drugset
drugset / Trial / NCT02194218

Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers

NCT02194218 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to determine the pharmacokinetic properties of 200 mg nevirapine (NVP) administered as 4 x 50 mg extended release (XR) tablets in a single dose and to establish the bioequivalence of this formulation compared to 200 mg NVP administered as 2 x 100 mg XR tablets in a single dose

Timeline

Start
2009-09
Primary completion
2009-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 50 mg Oral
Subject Nevirapine Small molecule 100 mg Oral

Indications

No indication recorded.